Effect of TMP-SMX prophylaxis on 1-year PCP incidence and related mortality in the propensity score-matched population (n=470)
| 1-year PCP incidence | 1-year PCP-related mortality* | |||
| HR (95% CI) | HR (95% profile likelihood CI) | |||
| Univariable analysis | Multivariable analysis† | Univariable analysis | Multivariable analysis‡ | |
| TMP-SMX prophylaxis | 0.07 (0.01 to 0.54) | 0.07 (0.01 to 0.53) | 0.07 (0.0005 to 0.55) | 0.08 (0.0006 to 0.71) |
| P value for HR | 0.010 | 0.010 | 0.007 | 0.019 |
*Firth’s penalised maximum likelihood was used due to complete separation of outcome.
†Included age and MPA as covariates, and was also adjusted for clustering.
‡Included age, GPA and MPA as covariates, and was also adjusted for clustering.
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.